MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignanciesGaurav S. Choudhary, Alexandru Almasan|Cell Death and Disease|2015Cited by 378